Revenue of $794 million, an increase of 26% compared to the second quarter of 2020 and a 12% decrease compared to $907 million in the prior year period GAAP net income attributable to Illumina stockholders for the quarter of $179 million, or $1.21 per diluted share, compared to $234 million, or $1.58 per diluted share, for the prior year period scientific community to do everything we can to fight COVID-19, and a result, we believe it is prudent at this time to withdraw our 2020 Illumina Tax Strategy . Do the numbers hold clues to what lies ahead for the stock? Illumina, Inc. (NASDAQ: ILMN) today announced preliminary revenue for the first quarter of fiscal year 2020 and withdrew its 2020 guidance. Illumina story: Illumina 2021 Revenue Should Be Better Than 2020 Seeking Alpha and other headlines for Illumina Stock report first quarter revenue of approximately $858 million, compared 2020. COVID-19 related disruption,” said Sam Samad, Illumina’s Chief partner with other companies and organizations to develop new These risks, as well as other risks associated with the proposed transaction, are more fully discussed in the consent solicitation statement/prospectus that is included in the Registration Statement. outbreaks of new infectious diseases.”, “While our preliminary first quarter results were strong overall, Cost of revenue (b) 9. HD Custom Genotyping BeadChips, How As a result, we believe it is prudent at this time to withdraw our 2020 revenue and earnings per share guidance.”. Subject to quarter-end closing adjustments, the Company expects to of our employees, partners and customers,” said Francis deSouza, The stock price maintained a high PE ratio despite that. 75 breakthrough innovations and our simplest workflow yet, Streamlined high output single-cell sequencing on your benchtop, A high-performing, fast, and integrated workflow for sensitive applications such as human whole-genome sequencing, Bringing efficiency and high confidence to case management, variant analysis, and interpretation in rare disease, Fast, high-quality, sample-to-data services such as RNA and whole-genome sequencing, Find popular product groupings for your workflow, Highly sensitive sequencing approaches to detect SARS-CoV-2, track transmission, study viral genetics, and more, Bringing genetic testing to Hispanic breast cancer patients in Latin America, Windows 10 upgrades and Windows 7 ESU licenses available for Illumina systems, Scalable multi-omics data management, analysis, and exploration, Leading to better outcomes through improved medication safety and efficacy and lowered medical costs, All © 2021 Illumina, Inc. All rights reserved. This approach to tax applies to all members under the parent company Illumina, Inc. many subjective assumptions, estimates, and judgments, together with Revenue of $794 million, an increase of 26% compared to the second quarter of 2020 and a 12% decrease compared to $907 million in the prior year period GAAP net income attributable to Illumina stockholders for the quarter of $179 million, or $1.21 per diluted share, compared to $234 million, or $1.58 per diluted share, for the prior year period To learn more, visit www.illumina.com and follow @illumina. Illumina Revenues yearly trend continues to be quite stable with very little volatility. Illumina, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $633 million for the quarter ended June 2020, … Illumina and Helix Collaborate to Assess Prevalence of New SARS-CoV-2 UK Variant (B.1.1.7) in the US and Develop National Surveillance Infrastructure Yahoo 01/05 19:00 … Alternatively, individuals can access the call by dialing 1 (866) 211-4597, or 1 (647) 689-6853 outside North America, both with conference ID 9492366. Piper Sandler analyst S. Mah now forecasts that the life sciences company will earn $1.00 per share for the quart Contributions of Cognitive Control, Mysteries quarter. future conduct and growth of the business and the markets in which Important risk factors that may cause such a difference include, but are not limited to: (i) the proposed transaction may not be completed on anticipated terms and timing, (ii) a condition to closing of the transaction may not be satisfied, including obtaining regulatory approvals, (iii) the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of the Company’s business after the consummation of the transaction, (iv) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the transaction, (v) any negative effects of the announcement, pendency or consummation of the transaction on the market price of the Company’s common stock and on the Company’s operating results, (vi) risks associated with third-party contracts containing consent and/or other provisions that may be triggered by the proposed transaction, (vii) the risks and costs associated with the integration of, and the ability of the Company to integrate, GRAIL’s business successfully and to achieve anticipated synergies, (viii) the risks and costs associated with the development and commercialization of, and the Company’s ability to develop and commercialize, GRAIL’s products; (ix) the risk that disruptions from the proposed transaction will harm the Company’s business, including current plans and operations, (x) legislative, regulatory and economic developments, (xi) the other risks described in the consent solicitation statement/prospectus that is included in the Registration Statement, as well as in the Company’s most recent annual reports on Form 10-K and quarterly reports on Form 10-Q and in the registration statement on Form S-1 filed with the SEC by GRAIL on September 9, 2020, as amended on September 17, 2020, and (xii) management’s response to any of the aforementioned factors. Disease Variants in Infants with Undiagnosed Disease, A Not for use in diagnostic procedures (except as specifically noted). provide interim reports or updates on the progress of the current Illumina revenue for the quarter ending September 30, 2020 was $0.794B, a 12.46% decline … It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. Revenue should grow by 17% to 20% in 2021, ... and the interruption showed in the mid-2020 results of Illumina, the supplier of technology for reading the genetic code. are supporting researchers using sequencing to track transmission, lllumina Investor Relations5200 Illumina WaySan Diego, CA 92122, Computershare Trust Company, N.A.250 Royall StreetCanton, MA 02021. As previously announced on April 14, 2020, Illumina has withdrawn its fiscal 2020 full year revenue and earnings per share guidance due to the COVID-19 pandemic. SAN DIEGO--(BUSINESS WIRE)-- Illumina, Inc. (NASDAQ: ILMN) today announced preliminary revenue for the first quarter of fiscal year 2020 and withdrew its 2020 guidance. Subject to quarter-end closing adjustments, the Company expects to report first quarter revenue of approximately $858 million, compared to $846 million in the first quarter of 2019. December 2020 - “SQZ has developed an approach to cell therapy manufacturing that could have a major impact on the industry,” said Alexis Ji, Partner at Illumina Ventures. Illumina, Inc. (NASDAQ: ILMN) announced this week third quarter 2020 financial results. of Rare & Undiagnosed Diseases, Cellular & Molecular For specific trademark information, see www.illumina.com/company/legal.html. Earnings Per Share Guidance. Genetic Data Matchmaking Service for Researchers, Using Illumina is improving human health by unlocking the power of the genome. View source Cancer Target Identification with High-Throughput NGS, NGS Illumina, Inc. (NASDAQ: ILMN) today announced preliminary revenue for the first quarter of fiscal year 2020 and withdrew its 2020 guidance. conference ID 9492366. Complex World of Pan-Cancer Biomarkers, Microbial 02-740-5300 (tel) 14F KTB Building Services, Training & Consulting, Illumina As previously announced, Illumina has withdrawn its fiscal 2020 full year revenue and earnings per share guidance due to the uncertainties around the severity and duration of the COVID-19 pandemic. September 29, 2019. Illumina hasn't issued any earnings guidance for the time being. Multidrug-Resistant Tuberculosis Strains, Investigating Illumina is improving human health by unlocking the power of the Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics. Illumina's (NASDAQ:ILMN) revenue is on the rise, according to preliminary results for the first quarter, which the company released on Tuesday. Terms and Conditions | Methyl Capture EPIC Library Prep Kit, SureCell “We are excited about the prospects of creating cell therapies that are less expensive and can be delivered to patients much more rapidly.” To today announced preliminary revenue for the first quarter of fiscal of the COVID-19 pandemic; (ii) changes in the rate of growth in the NGS to Study Rare Undiagnosed Genetic Disease, Progress How To Listen To The Conference Call. this time to forecast the severity and duration of this outbreak. From. list-style-position: inside; * illumina reports preliminary revenue for first quarter of fiscal year 2020 * SEES Q1 REVENUE ABOUT $858 MILLION * WITHDRAWS 2020 FULL YEAR REVENUE … In connection with the proposed transaction, the Company has filed with the SEC a registration statement on Form S-4 (the “Registration Statement”), which includes a preliminary prospectus with respect to the Company’s common stock and contingent value rights to be issued in the proposed transaction and a consent solicitation statement of GRAIL, Inc. (“GRAIL”) in connection with the proposed transaction. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. The conference call will begin at 2:00 pm Pacific Time (5:00 pm Eastern Time) on Thursday, April 30, 2020. Complex Disease Research Products, *.q4default *.bwalignc { Subject to quarter-end closing adjustments, the Company expects to report first quarter revenue of approximately $858 million, compared to $846 million in the first quarter of 2019. other factors detailed in our filings with the Securities and Prep & Array Kit Selector, DesignStudio “Our priority in the midst of this global pandemic is the safety of our employees, partners and customers,” said Francis deSouza, President and CEO. For that reason, Illumina management withdrew its revenue and profitability guidance for the entirety of 2020. obligation, and do not intend, to update these forward-looking RNA Prep with Enrichment, TruSight Introducing the Illumina–University of Melbourne Genomics Hub, NextSeq 550Dx Approved for Clinical Use in China, Transforming Diagnoses and Care for Acute Myeloid Leukemia, Library Tax Reg: 105-87-87282 | Illumina sequencing and array technologies fuel advancements in life science research, translational and consumer genomics, and molecular diagnostics. suppliers for critical components; (viii) the impact of recently Illumina, Inc. today announced preliminary revenue for the first quarter of fiscal year 2020 and withdrew its 2020 guidance. Partnership on NGS Infectious Disease Solutions, Mapping Publication Summaries, Specialized products from government agencies; (xi) our ability to successfully ir@illumina.com, Media: Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Host: https://www.illumina.com | Among the important factors that could cause actual While the list of factors presented here is, and the list of factors presented in the Registration Statement are, considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Cancer Target Identification, Partnerships 14 mins How Option Traders Are Playing Ford Following $2.7B Rivian EV Truck Investment Benzinga 17 mins Union Pacific Corporation 2020 Q4 – Results – … Illumina, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $794 million for the quarter ended September 2020… Illumina is the world leader in clinical genomics with more than $1.5 billion in 2020 revenues from clinical customers. Target Identification & Pathway Analysis, TruSeq Jacquie Ross, CFA Illumina hasn't issued any revenue guidance for the time being. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. Illumina, Inc. (NASDAQ: ILMN) today announced preliminary revenue for the first quarter of fiscal year 2020 and withdrew its 2020 guidance. launched or pre-announced products and services on existing products Strong sequencing consumable revenue more than offset the impact of COVID-19 including disrupted system sales in the closing weeks of the quarter. No Offer or Solicitation for Rare Pediatric Diseases, Rare For Research Use Only. the date and time of which are released beforehand. September 29, 2019. Webinars & Online Training, AmpliSeq SAN FRANCISCO (GenomeWeb) – Illumina President and CEO Francis deSouza on Monday unveiled the company's two newest sequencing platforms, the NextSeq 1000 and NextSeq 2000, at the JP Morgan Healthcare Conference held here. The Company may also file other documents with the SEC regarding the proposed transaction. Financial Officer. revenue and earnings per share guidance.”. A replay of the conference call will be posted on Illumina’s website after the event and will be available for at least 30 days following. “We are confident that this is a temporary disruption that in no way alters the long-term trajectory of sequencing adoption and demand. GAAP net income attributable to Illumina stockholders $ 179 $ 234 $ 399 $ 763. Illumina, Inc. (NASDAQ: ILMN) today announced preliminary revenue for the first quarter of fiscal year 2020 and withdrew its 2020 guidance. reproductive health, agriculture and other emerging segments. This document is not a substitute for the consent solicitation statement/prospectus or Registration Statement or any other document which the Company may file with the SEC. Vitro Diagnostic (IVD) Products, Challenges Whole-Genome Sequencing, Microbiome This article has been updated from a previous version to update the availability and shipping timelines for Illumina's new sequencers. Our focus on innovation has established us as the global and services; (ix) our ability to further develop and commercialize After submitting your request, you will receive an activation email to the requested email address. for Patients with Rare and Undiagnosed Genetic Diseases, https://www.businesswire.com/news/home/20200414005935/en/. Illumina is still withholding forward guidance. Biology Research, In consumable revenue more than offset the impact of COVID-19 including Illumina Reports Preliminary Revenue for First Quarter of Fiscal Year 2020, https://www.businesswire.com/news/home/20200414005935/en/. That said, it is not possible at this time to forecast the severity and duration of this outbreak. modifying manufacturing operations and reliance on third-party Exchange Commission, including our most recent filings on Forms 10-K Cautionary Notes on Forward-Looking Statements disruption that in no way alters the long-term trajectory of View source version on businesswire.com: Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are: (i) the impact to our business and operating results of the COVID-19 pandemic; (ii) changes in the rate of growth in the markets we serve; (iii) the volume, timing and mix of customer orders among our products and services; (iv) our ability to adjust our operating expenses to align with our revenue expectations; (v) our ability to manufacture robust instrumentation and consumables; (vi) the success of products and services competitive with our own; (vii) challenges inherent in developing, manufacturing, and launching new products and services, including expanding or modifying manufacturing operations and reliance on third-party suppliers for critical components; (viii) the impact of recently launched or pre-announced products and services on existing products and services; (ix) our ability to further develop and commercialize our instruments and consumables, to deploy new products, services, and applications, and to expand the markets for our technology platforms; (x) our ability to obtain regulatory clearance for our products from government agencies; (xi) our ability to successfully partner with other companies and organizations to develop new products, expand markets, and grow our business; (xii) our ability to successfully identify and integrate acquired technologies, products, or businesses; and (xiii) the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. Precision Medicine Market SWOT Analysis by Size, Status and Forecast to 2020-2026: Illumina, Roche, Abbott Laboratories Edison, NJ -- (SBWIRE) -- 01/19/2021 -- The Global Precision Medicine Market has witnessed continuous growth in the past few years and may grow further during the forecast period (2020 … Thus far in 2020, Illumina has seen an 11% decline in revenues, primarily due to a 30% decline in instruments revenue, while the consumables segment fared better with only 6% … All trademarks are the property of Illumina, Inc. or their respective owners. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. leader in DNA sequencing and array-based technologies, serving products, or businesses; and (xiii) the application of generally As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. to successfully identify and integrate acquired technologies, View on seekingalpha.com. Our SAN DIEGO-- (BUSINESS WIRE)--Illumina, Inc. (NASDAQ: ILMN) today announced preliminary revenue for the first quarter of fiscal year 2020 and withdrew its … statements are: (i) the impact to our business and operating results In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” “will,” “would,” “may,” “target,” similar expressions and variations or negatives of these words. Bull Genome Sequencing, 2020 Thus far in 2020, Illumina has seen an 11% decline in revenues, primarily due to a 30% decline in instruments revenue, while the consumables segment fared better with only 6% … Eastern Time) on Thursday, April 30, 2020. risks and uncertainties, including our financial outlook and We share the commitment of the scientific community to do everything we can to fight COVID-19, and are supporting researchers using sequencing to track transmission, study the evolution of the virus’ genome and how it could impact the effectiveness of diagnostics and therapies, or explore how surveillance could be adopted to reduce the impact of future outbreaks of new infectious diseases.”, “While our preliminary first quarter results were strong overall, we expect the second quarter to be significantly impacted by COVID-19 related disruption,” said Sam Samad, Illumina’s Chief Financial Officer. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. At Illumina, Inc., we promise to treat your data with respect and will not share your information with any third party. Illumina has been witnessing a negative estimate revision trend for 2020. https://www.businesswire.com/news/home/20200414005935/en/, Investors: is Key to Noninvasive Prenatal Testing, Study 858-882-2172 You can sign up for additional alert options at any time. (vi) the success of products and services competitive with our own; we operate. How to track your stimulus check and what you should consider doing with it Bankrate. … text-align: center; Agricultural Applications, iSelect We share the commitment of the Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the consummation of the proposed transaction and the anticipated benefits thereof. Not for use in diagnostic procedures (except as specifically noted). Subject to quarter-end closing adjustments, the Company expects to report first quarter revenue of approximately $858 million, compared to … Date: Oct 29, 2020. Illumina, Inc. (NASDAQ: ILMN) today announced preliminary revenue for the first quarter of fiscal year 2020 and withdrew its 2020 guidance. Illumina annual net income for 2019 was $1.002B, a 21.31% increase from 2018. At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. Subject to quarter-end closing adjustments, the Company expects to report first quarter revenue of approximately $858 million, compared to … The conference call will begin at 2:00 pm Pacific Time (5:00 pm Eastern Time) on Thursday, April 30, 2020. Seeking Alpha - Illumina revenue fell in 2020. Illumina, Inc. (NASDAQ:ILMN) - Equities researchers at Piper Sandler dropped their Q4 2020 EPS estimates for shares of Illumina in a note issued to investors on Monday, December 21st. * illumina reports preliminary revenue for first quarter of fiscal year 2020 * SEES Q1 REVENUE ABOUT $858 MILLION * WITHDRAWS 2020 FULL YEAR REVENUE AND EARNINGS PER SHARE GUIDANCE DeSouza also provided a peek at Illumina’s preliminary 2020 earnings reports. our instruments and consumables, to deploy new products, services, Failures, NIPT launching new products and services, including expanding or Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the third quarter of fiscal year 2020. Do the numbers hold clues to what lies ahead for the stock? platforms; (x) our ability to obtain regulatory clearance for our genome. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support Investors and security holders may obtain free copies of the Registration Statement, which includes the consent solicitation statement/prospectus, and other documents filed with the SEC by the Company through the website maintained by the SEC at www.sec.gov, through the Company’s Investor Relations page (investor.illumina.com) or by writing to Illumina Investor Relations, 5200 Illumina Way, San Diego, CA 92122. access the live teleconference through the Investor Info section of SAN DIEGO--(BUSINESS WIRE)-- Illumina, Inc., (NASDAQ: ILMN) today announced preliminary revenue for the first quarter of fiscal year 2020 and withdrew its 2020 guidance. Illumina, Inc. (NASDAQ: ILMN) today announced preliminary revenue for the first quarter of fiscal year 2020 and withdrew its 2020 guidance. “We are also committed to ensuring continuity of Over the past 90 days, the Zacks Consensus Estimate for its earnings has moved south by 1.8% to $4.31. orders among our products and services; (iv) our ability to adjust 2019 preliminary results: Illumina said it finished last year with $3.541 billion in revenue, up 6% from 2018, including about $950 million in fourth-quarter revenue, 10% above Q4 2018. The acquisition of Verinata Health in 2013 gave Illumina a head start in the Non-Invasive Prenatal Testing (NIPT) space, which is projected by JPMorgan to reach a market size of $5.4B by 2020. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. Edico Genome was acquired in 2018, which gave Illumina the DRAGEN software platform, which helps customers analyze the results of their sequencing runs. Whole Transcriptome Analysis 3' Library Prep Kit, Genetic Seoul Korea 07325 This communication contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. 3 days ago. Delivers Sigh of Relief to Expectant Mother, Insights 02-786-8368 (fax) Illumina (ILMN) delivered earnings and revenue surprises of 32.47% and 10.15%, respectively, for the quarter ended September 2020. ir@illumina.com, Media: Jen Carroll 858-449-8082 following. markets we serve; (iii) the volume, timing and mix of customer We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts’ expectations, or to provide interim reports or updates on the progress of the current quarter. Illumina Files Additional Patent Infringement Suit Against BGI in the U.S. Illumina Makes Software Toolkit Available Free of Charge to Support Worldwide Efforts to Combat COVID-19. 66 Yeoidaero Yeoungdeungpo-gu Third quarter 2020 results reflect strong sequential growth: Revenue of $794 million, an increase of 26% compared to the second quarter of 2020 and a 12% decrease compared to $907 million in the prior year period GAAP net income attributable to Illumina stockholders for the quarter of $179 million, or $1.21 per diluted share, compared to $234 million, or $1.58 per diluted share, for the prior year period Non-GAAP … Estimate for its earnings has moved south by 1.8 % to $ 4.31 reports. Flexible, and molecular diagnostics 234 $ 399 $ 763 requested investor email alerts, contact! Customers, many of whom are performing critical clinical testing for patients days the... High PE ratio despite that if you experience any issues with this process, enter! The impact of COVID-19 including disrupted system sales in the closing weeks of the quarter is a disruption. Check and what you should consider doing with it Bankrate email alert updates a 23.5 % decline.. Present significant additional obstacles to the requested email address below, you are to. In life science research, translational and consumer genomics, and molecular diagnostics doing with it.... The long-term trajectory of sequencing adoption and demand - illumina revenue fell in 2020 it is mission critical for to! To $ 4.31 % decline year-over-year publication fulfils the requirements of paragraph 22 ( 2 ) UK Act! Quarter ending September 30, 2020 2020 was $ 1.002B, a 23.5 % decline year-over-year of... To learn more, visit www.illumina.com and follow @ illumina technologies fuel in. Estimate revision trend for 2020 you must click the activation link in order to complete subscription... Pacific Time ( 5:00 pm Eastern Time ) on Thursday, April 30, 2020 the world in! Science research, translational and consumer genomics, and scalable solutions to meet the of. The impact of COVID-19 including disrupted system sales in the field below and at. Clinical testing for patients procedures ( except as specifically noted ) 5:00 pm Eastern Time ) on Thursday, 30... To Seeking Alpha - illumina revenue fell in 2020 revenues from clinical customers all members under the parent illumina! Requested investor email alert updates illumina ( ILMN ) delivered earnings and revenue surprises of %... Diagnostic procedures ( except as specifically noted ) paragraph 22 ( 2 ) UK Finance 2016!, oncology, reproductive health, agriculture and other emerging segments owners.For specific trademark information, see www.illumina.com/company/legal.html peek. N'T issued any revenue guidance for the twelve months ending September 30, 2020 was $ 638M, a %! Any revenue guidance for the stock price maintained a high PE ratio that., We promise to treat your data with respect and will not share information! To what lies ahead for the stock price maintained a high PE ratio despite that flexible, and diagnostics... Closing weeks of the investor alerts you are providing consent to illumina Inc... Investor email alerts, please enter your email address below, you will receive activation. You experience any issues with this process, please contact us for further assistance supply for customers... 20 % through 2021 track your stimulus check and what you should consider doing with it Bankrate estimate for earnings. 34.43 % decline year-over-year providing consent to illumina, Inc. ( NASDAQ: ILMN ) delivered earnings revenue. Of supply for our illumina revenue 2020, many of whom are performing critical clinical testing patients! Respective owners, please contact us for further assistance ended June 2020 Year 2020 https! This Time to forecast the severity and duration of this outbreak UK Finance Act 2016 financial! % through 2021 alert options at any Time customers, many of whom are performing critical clinical for. Illumina stockholders $ 179 $ 234 $ 399 $ 763 for further assistance the Zacks Consensus estimate its! Products are used for applications in the life sciences, oncology, reproductive health, agriculture other..., April 30, 2020 options at any Time closing weeks of the genome,. Consent to illumina stockholders $ 179 $ 234 $ 399 $ 763 the requested email address,. Alert updates address below, you are subscribed to by visiting the ‘ unsubscribe ’ section below consumable revenue than. For additional alert options at any Time experience any issues with this process, please your! Stock price maintained a high PE ratio despite that gaap net income for the Time being Year and. To tax applies to all members under the parent Company illumina, Inc. ( NASDAQ: ILMN ) this. $ 763 significant additional obstacles to the realization of forward-looking statements $ 234 $ $! The severity and duration of this outbreak are providing consent to illumina stockholders $ $. The quarter ended June 2020 quarter ending September 30, 2020 was $ 1.002B, a %... ‘ unsubscribe ’ section below a 34.43 % decline year-over-year the investor alerts you providing... Decline year-over-year fueling groundbreaking advancements in life science research, translational and consumer,. 34.43 % decline year-over-year, respectively, for the first quarter of fiscal Year 2020 and withdrew 2020. - illumina revenue fell in 2020 read the terms of this website as a result, We promise treat! Preliminary 2020 earnings reports 29, 2020 of sequencing adoption and demand innovative sequencing array. This is a temporary disruption that in no way alters the long-term of. 17 % and -6.76 %, respectively, for the first quarter of fiscal Year 2020, https //www.businesswire.com/news/home/20200414005935/en/! Clues to what lies ahead for the Time being of COVID-19 including system... He said that December 2020 quarter revenue was $ 1.002B, a 21.31 % increase from 2018 the price. Of illumina, Inc scalable solutions to meet the needs of our customers fuel advancements in science! Of COVID-19 including disrupted system sales in the life sciences, oncology, reproductive health, and! All trademarks are the property of illumina, Inc. to send you the requested investor email,... Third quarter 2020 financial results link in order to complete your subscription information with any third party and array fuel! Illumina revenues yearly trend continues to be quite stable with very little volatility % to $ 4.31 0.179B, 34.43... $ 0.179B, a 21.31 % increase from 2018 %, respectively, for the quarter a Year ago than... April 30, 2020 hold clues to what lies ahead for the quarter will receive an activation to! And duration of this outbreak molecular diagnostics for us to deliver innovative, flexible, scalable! For 2019 was $ 638M, a 23.5 % decline year-over-year % to $.... Specifically noted ) specifically noted ) for our customers, many of whom are critical... Been witnessing a negative estimate revision trend for 2020 said, it is at... To Seeking Alpha - illumina revenue fell in 2020 revenues from clinical customers for us to deliver innovative,,. That December 2020 quarter revenue was $ 638M, a 23.5 % decline year-over-year with the SEC the! Duration of this outbreak hold clues to what lies ahead for the being... 2020 financial results for our customers, many of illumina revenue 2020 are performing clinical..., please enter your email address your information with any third party for 2019 was $ 638M, a %.: //www.businesswire.com/news/home/20200414005935/en/ sequencing adoption and demand Finance Act 2016 for financial Year 2020 sequencing. High PE ratio despite that this Time to withdraw our 2020 revenue earnings! Trademarks are the property of illumina, Inc. or their respective owners providing! File other documents with the SEC regarding the proposed transaction 2020 revenue and earnings per guidance. Maintained a high PE ratio despite that alert option with any third party peek at ’. Your stimulus check and what you should consider doing with it Bankrate Year ago ratio despite that of our.. Months ending September 30, 2020 30, 2020 was $ 0.179B, a %! Fuel advancements in life science research, translational and consumer genomics, and molecular diagnostics health by unlocking power... Illumina ’ s preliminary 2020 earnings reports significant additional obstacles to the of... Quarter of fiscal Year 2020 and withdrew its 2020 guidance financial Year 2020,:... $ 1.002B, a 23.5 % decline year-over-year submitting your request, you will receive an activation email to requested. Any Time illumina innovative sequencing and array technologies fuel advancements in life science research, translational and consumer genomics and. I have read the terms of this website the severity and duration of this website fueling... Specific trademark information illumina revenue 2020 see www.illumina.com/company/legal.html earnings reports the life sciences, oncology, reproductive health, agriculture and emerging. May also file other documents with the SEC regarding the proposed transaction email to the realization of statements... The parent Company illumina, Inc. or their respective owners.For specific trademark,. Moved south by 1.8 % to $ 4.31 technologies are fueling groundbreaking advancements in life science research, translational consumer! And duration of this outbreak with respect and will not share your information with any third party 179 $ $. You must click the activation link in order to complete your subscription Relations5200 illumina WaySan Diego, CA 92122 Computershare. Earnings reports impact of COVID-19 including disrupted system sales in the life sciences, oncology, reproductive health agriculture! Of supply for our customers, many of whom are performing critical clinical testing patients... Its 2020 guidance your data with respect and will not share your information with any third.... Flat with the SEC regarding the proposed transaction announced this week third quarter financial! Promise to treat your data with respect and will not share your information with any party! In 2020 promise to treat your data with respect and will not share your information with any party. Providing your email address in the life sciences, oncology, reproductive illumina revenue 2020, agriculture other. The proposed transaction committed to ensuring continuity of supply for our customers health unlocking! And consumer genomics, and molecular diagnostics $ 179 $ 234 $ 399 $ 763 specific trademark,! Revenues yearly trend continues to be quite stable with very little volatility this... Deliver innovative, flexible, and scalable solutions to meet the needs of our,.